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Hypertensive disorders of pregnancy (gestational hypertension, 
pre-eclampsia, eclampsia and chronic hypertension) are a major 
cause of maternal mortality in South Africa (SA) and worldwide. 
The most recent Saving Mothers report (2011 - 2013)[1] indicates that 
14.8% of all maternal deaths were due to hypertensive disorders of 
pregnancy (HDP). This publication, which is the triennial report of 
the National Committee for Confidential Enquiries into Maternal 
Deaths (NCCEMD) in SA, also indicates that the final cause of death 
in >50% of hypertensive maternal mortality was probably associated 
with cerebral injury, particularly in cases of severe pre-eclampsia 
and eclampsia. In addition, the majority of deaths occurred in young 
women in their first pregnancies and a large proportion (>60%) were 
avoidable.[1]
Although severe HDP may cause other target organ damage 
such as renal impairment and pulmonary oedema, the authors have 
chosen to elaborate on cerebral injury, given the Saving Mothers 
report on the association between untreated severe hypertension and 
cerebral haemorrhage.[1] Moreover, in the authors’ clinical experience 
and according to findings in recent reports, severe hypertension 
often precedes other cerebral manifestations such as blindness in 
pregnancy, stroke, altered mental state and the posterior reversible 
encephalopathy syndrome (PRES).[2-6]
PRES and severe hypertension  
in pregnancy
A known maternal cerebral complication of severe pre-eclampsia 
is PRES.[2] This syndrome is a clinico-neuroimaging entity and 
is hypothesised to be related to impaired cerebral blood flow 
autoregulation that leads to either over- or under-perfusion of the 
brain. On magnetic resonance imaging and computed tomography 
scans of the brain, oedema is seen mainly in the subcortical white 
matter and occasionally in the cortex of the occipital and parietal 
lobes.[3] Recently, Van Veen et al.[4] investigated cerebral blood flow 
autoregulation by measuring cerebral artery blood flow velocity using 
transcranial Doppler ultrasound and found impaired autoregulation 
in women with pre-eclampsia when compared with those who had 
gestational hypertension or normal pregnancies. There is therefore 
increasing evidence that impaired cerebral blood flow autoregulation 
plays a central pathological role in cerebral manifestations associated 
with pre-eclampsia/eclampsia syndrome.
Symptoms of PRES include persistent headache, nausea, vomiting, 
visual disturbances, confusion and seizures. These clinical signs are 
well known by obstetricians to herald seizures and other features of 
cerebral dysfunction. Eclampsia is reported to be one of the most 
important causes of PRES, and although most patients have severe 
hypertension, some have mildly elevated or even normal blood 
pressure (BP).[2,4] 
It has been reported that PRES is reversible and that initiating 
early treatment of severe hypertension leads to cure, while delayed 
recognition of symptoms and cognisance of the need to lower high 
BP judiciously but immediately leads to cerebral injury.[2,3] The 
Saving Mothers report (2011 - 2013)[1] indicates that one of the 
avoidable health professional factors leading to maternal mortality 
is failure to institute appropriate and prompt management of 
severe systolic and diastolic hypertension in the ante-, intra- and 
postpartum periods.
Immediate treatment of severe 
hypertension in pregnancy
Standardised clinical protocols for the management of severe pre-
eclampsia and eclampsia have been shown to reduce complications 
associated with this hypertensive disorder.[7-9] In pregnancy, 
acute-onset severe hypertension that is accurately measured using 
standard techniques and persistent for ≥15 minutes is regarded 
as a hypertensive emergency.[7-9] If not adequately treated, severe 
hypertension can cause cerebral injury. A systolic BP of >160 mmHg 
is included in the definition of severe hypertension in pregnancy. 
Severe diastolic hypertension of ≥110 mmHg is also regarded as 
a hypertensive emergency.[7-10] Pregnant women with acute-onset, 
severe systolic and/or diastolic BPs in the ante-, intra-, or immediate 
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postpartum periods therefore warrant antihypertensive treatment. 
The goal should be to lower high BP levels to a range of 140 - 150/90 - 
100 mmHg in order to prevent repeated prolonged exposure of 
the patient to severe systolic hypertension with subsequent loss of 
cerebral vasculature autoregulation.[10]
Some case scenarios and the ‘5 Rs’ in 
severe hypertension in pregnancy
If health professionals are aware that severe hypertension in preg-
nancy may result in cerebral injury, what should they do when they 
are faced with such clinical situations in an SA setting?
Health professionals must be aware of the 5 Rs:
1.  Recognition that acute-onset severe hypertension (≥160 mmHg systolic 
or ≥110 mmHg diastolic BP) in pregnant women is a MAJOR ALERT
2.  Responding by notifying a specialist or seeking advice from the 
most appropriate health professional
3.  Responsibility: taking responsibility to initiate early anti-
hypertensive therapy and provide close monitoring until the 
patient is stabilised
4.  Reviewing the clinical situation once high BP is stabilised
5.  Realising that effective high BP control is merely a surrogate 
marker of maternal and neonatal outcome; components such as 
fetal assessment, prevention of seizures (eclampsia), expeditious 
delivery and post-delivery care must therefore be considered.[1-10]
Case scenarios
Health professionals may be faced with women with acute-onset 
severe hypertension in varying clinical scenarios. These include:
• In the antenatal period. When hypertension occurs in this setting, 
the patient should be admitted to hospital immediately and 
the high BP should be stabilised before delivery, even in urgent 
situations.[1] Lowering of the high BP should occur in a high-care 
area, or a dedicated bed selected for this purpose.
• If transfer from a district health facility to a regional/tertiary centre 
is required, the high BP should be stabilised and other measures 
such as the administration of magnesium (in cases of severe pre-
eclampsia and/or eclampsia) started before transfer. Monitoring 
must continue while awaiting an ambulance for the transfer.
• When the diagnosis of acute-onset severe pre-eclampsia is made in 
an office setting, available emergency treatment should be initiated 
and the patient expeditiously sent to a regional/tertiary hospital for 
treatment and further management.
• If any hospitalised patient with pre-eclampsia has either a systolic 
BP of 160 mmHg or a diastolic BP of 110 mmHg, the automatic 
response should be initiating a rapid-acting antihypertensive agent 
such as nifedipine 10 mg orally, labetalol 20 mg intravenously (IV) 
or hydralazine 5 - 10 mg IV.[9,10]
• Induction of anaesthesia and intubation. In a setting in which 
the patient may require endotracheal intubation in a labour ward 
(high-care bed), an operating theatre or an intensive care unit, 
it should be recognised that endotracheal intubation increases 
the BP and should therefore not be undertaken without prior 
measures to prevent or minimise the hypertensive response to 
intubation.
• Acute-onset severe hypertension in the postpartum period. 
Onset may occur for the first time after delivery, or it may be 
superimposed on women with chronic hypertension, gestational 
hypertension and those with mild to moderate pre-eclampsia. 
In women with such diagnoses, long-acting antihypertensive 
therapy must therefore be maintained after delivery and not 
stopped abruptly. In the clinical setting of postpartum acute-
onset severe hypertension, the same treatment, viz. rapid-acting 
antihypertensive agents, must be used to stabilise systolic and/or 
diastolic hypertension.
In general terms, healthcare professionals must provide close 
maternofetal monitoring during the stabilisation of acute-onset 
severe hypertension. Judicious fluid administration is recommended, 
especially in the oedematous pre-eclamptic patient with oliguria and 
laboratory signs of renal dysfunction. Fluid balance and signs of early 
pulmonary oedema must therefore be given careful attention. After 
initial BP stabilisation, close monitoring should be carried out and a 
maintenance dose of antihypertensive(s) given.
Over the past decade, the use of clinical protocols and dynamic 
checklists has become a standard approach to ensure patient safety 
and improve the care provided to mothers and their newborns.[11] The 
clinical management of severe acute-onset pregnancy hypertension 
lends itself to dynamic checklists.
First-line antihypertensive therapy for 
acute-onset severe hypertension
IV labetalol, IV dihydralazine and oral nifedipine are the commonly 
used antihypertensive agents. The contraindications to and 
compelling indications for the available rapid-acting agents must be 
considered when choosing a particular drug. Magnesium sulphate 
is not recommended as an antihypertensive agent, but remains 
the drug of choice for seizure prophylaxis in severe pre-eclampsia 
and for controlling seizures in eclampsia.[12] Nifedipine may be the 
more appropriate antihypertensive agent in a setting of primary 
healthcare clinics and midwifery obstetric units because it can be 
given orally. [13,14] Intravenous agents (labetalol or dihydralazine if 
available) are preferable if the patient is restless or semiconscious or 
in a hospital setting.
Fig. 1 outlines the steps for the use of rapid-acting antihypertensive 
agents for acute-onset severe hypertension during pregnancy and the 
postpartum period.
It should be noted that dihydralazine is not available in most 
provinces of SA. Oral nifedipine and/or labetalol should therefore 
be a ‘stock item’ for all hospitals providing healthcare for pregnant 
women. Both of these drugs are available in public sector hospitals in 
SA. The common contraindications of rapid-acting antihypertensive 
agents are shown in Table 1. All the agents listed may cause severe 
hypotension, but these events are rare. It is suggested that where 
possible fetal heart rate monitoring should be done at the same time 
as the lowering of very high BP.
Key points
• There is consensus that sustained severe hypertension in pregnancy 
should be lowered immediately in a controlled manner to reduce 
the risk of cerebral complications.
• A systolic BP of 160 mmHg is suggested as the most appropriate 
threshold for defining severe maternal hypertension.
• If threshold systolic BP levels are sustained or occur with a 
combin ation of symptoms suggesting maternal cerebral compli-
cations, immediate use of rapid-acting antihypertensive agents 
is essential.
• The goal of rapid-acting antihypertensive agents should be to 
achieve a BP of 140 - 150/90 - 100 mmHg.
• Use of dynamic checklists is essential for the management of acute-
onset severe pregnancy hypertension.
Conclusion
Severe hypertension in pregnancy is an emergency (major alert) that 
requires immediate attention. An inappropriately managed severe 
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hypertensive condition may result in cerebral haemorrhage. Timely 
action to reduce sustained systolic hypertension judiciously by means 
of a rapid-acting antihypertensive drug will reduce maternal and 
neonatal mortality and morbidity.
Severe hypertension in pregnancy 
Regard as a MAJOR ALERT BP ≥160 mmHg systolic, or ≥110 mmHg
diastolic; therefore inform the most senior/experienced 
obstetrician/medical ocer/fetomaternal specialist. 
Institute fetal surveillance if the fetus is viable. 
Aim to achieve a goal BP of 140 - 150/90 - 100 mmHg. 
Is patient conscious and able to tolerate oral medication? 
If severe hypertension persists for ≥15 minutes,
administer nifedipine tablet (10 mg orally). 
Re-check BP after 20 minutes. 
If there is still severe hypertension, administer nifedipine
tablets (20 mg orally). If the BP is successfully reduced
below the severe hypertension threshold, continue
BP monitoring closely. 
Re-check BP after 20 minutes. 
Re-check BP after 20 minutes. 
If there is still severe hypertension, administer nifedipine
tablets (20 mg orally). If the BP is successfully reduced
below the severe hypertension threshold, continue
BP monitoring closely.
Administer additional antihypertensive therapy as per
specic order. 
Once the desired BP is achieved: 
•   re-check BP every 10 minutes for the next 1 hour
•   then re-check BP every 15 minutes for the next 1 hour
•   then re-check BP every 30 minutes for the next 1 hour
•   then re-check BP every 1 hour for the next 4 hours.
If the high BP persists for ≥15 minutes or if there are
symptoms of impending eclampsia (nausea and vomiting,
severe headache, epigastric pain, visual disturbances),
administer labetalol 20 mg IV slowly over 2 minutes. 
Check BP after 10 minutes. 
If there is still severe hypertension, administer IV labetalol
40 mg over 2 minutes. Should the BP be successfully reduced
below the severe hypertension threshold, continue
BP monitoring closely.
Check BP after 10 minutes. If there is still severe hypertension,
administer IV labetalol 80 mg over 2 minutes. If the BP is
successfully reduced below severe hypertension
threshold, continue BP monitoring closely. 
Check BP after 10 minutes. If there is still severe hypertension,
obtain emergency consultation from one of the following:
fetomaternal specialist, internal medicine specialist, obstetric
anaesthetist or critical care specialist.
Administer additional antihypertensive drug as per specic
order (in SA this is usually methyldopa 500 mg 6-hourly). 
Once the desired BP is achieved: 
•   re-check BP every 10 minutes for the next 1 hour
•   then re-check BP every 15 minutes for the next 1 hour
•   then re-check BP every 30 minutes for the next 1 hour
•   then re-check BP every 1 hour for the next 4 hours
•   then re-check BP every 4 hours.
Commence additional antihypertensive therapy
per specic order. 
Note: Hydralazine (5 mg or 10 mg IV over 2 minutes) may be the initial antihypertensive administered. After 20 minutes,
an additional 10 mg may be administered. In the next 20 minutes, 20 mg may be administered. Then re-check BP
after 10 minutes; if there is still severe hypertension, request emergency consultation and commence labetalol
40 mg IV over 2 minutes. 
Yes No
Fig. 1. Algorithm for the initial control of BP in severe hypertension in pregnancy.
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Table 1. Common contraindications of the rapid-acting antihypertensive agents
Cautions Contraindications
Nifedipine Hypertrophic obstructive cardiomyopathy, aortic stenosis. The 
capsules cause a reflex increase in sympathetic tone which 
should be avoided in women with increased myocardial oxygen 
demands, e.g. fixed valvular obstruction.
Unstable angina, congestive heart failure, myocardial infarction
Labetalol Controlled heart failure, hepatic disorder. Best avoided in 
women with asthma. Parenteral labetalol may cause neonatal 
bradycardia, but is not a major problem in clinical practice.
Heart failure with symptoms, 2nd and 3rd degree 
atrioventricular block, severe bronchospasm, asthma, sinus 
bradycardia
Hydralazine Renal or hepatic impairment, porphyria, angina. It causes a reflex 
increase in sympathetic tone and should therefore be avoided for 
women in whom increased myocardial oxygen demands could be 
dangerous, e.g. coronary artery disease, mitral stenosis.
Systemic lupus erythematosus, aortic stenosis, tachycardia, 
hypertrophic obstructive cardiomyopathy
